Marta Rybczynski

News

Ibrutinib Safe, Effective for the Treatment of Relapsed/Refractory CLL

12/07/2021

Findings from a real-world study suggest that using single-agent ibrutinib for relapsed/refractory CLL is safe and effective in routine clinical practice.

Findings from a real-world study...

12/07/2021

Journal of Clinical Pathways

Conference Coverage

Testing Hospital-Based Financial Toxicity Interventions at Memorial Sloan Kettering Cancer Center

10/01/2022

Marta Rybczynski ;

At least a quarter of patients at Memorial Sloan Kettering Cancer Center suffer with financial difficulties related to cancer treatment, suggesting a need for systems-based interventions to proactively assess financial toxicity risk and refer...

At least a quarter of patients...

10/01/2022

Journal of Clinical Pathways

News

Disease Progression After Olaparib Maintenance Prognosticates Poor Response to Subsequent Platinum-Based Chemotherapy in Ovarian Cancer

03/01/2022

Marta Rybczynski ;

Patients with platinum-sensitive, recurrent ovarian cancer whose disease progressed following olaparib maintenance experienced poor response to subsequent platinum-based chemotherapy, according to a recent study.

Patients with...

03/01/2022

Journal of Clinical Pathways

Conference Coverage

Changes in PROs Can Predict Treatment Response and Survival in Metastatic Gastrointestinal Cancer

10/04/2021

Marta Rybczynski ;

Results from a study presented at the 2021 ASCO Quality Care Symposium showed that 1-month changes in patient-reported outcomes predicted treatment responses and survival outcomes among patients with metastatic GI cancer.

Results from a study presented...

10/04/2021

Journal of Clinical Pathways

News

Decision Analytical Model Optimizes Posttreatment Surveillance Strategies Among Patients With Oropharyngeal Carcinoma

04/29/2022

Marta Rybczynski ;

When compared with common medical reimbursement guidelines, model-optimized strategies may be associated with lower detection latency without requiring any additional imaging studies among patients with oropharyngeal carcinoma.

When compared with common...

04/29/2022

Journal of Clinical Pathways

News

Budget Impact Analysis of Biosimilar Bevacizumab for Patients With Cancer

12/09/2021

Marta Rybczynski ;

Study findings indicate that the introduction of biosimilar bevacizumab-bvzr may provide substantial cost savings from the US payers’ perspective, allowing for the bevacizumab treatment to become accessible to more patients.

Study findings indicate that the...

12/09/2021

Journal of Clinical Pathways

News

Trastuzumab Biosimilars Safe, Effective Among Patients With HER2-Positive Breast Cancer

03/07/2022

Marta Rybczynski ;

Study findings show that trastuzumab biosimilars are safe and effective compared to the reference drug and improve patients' accessibility to breast cancer treatment.

Study findings show that...

03/07/2022

Journal of Clinical Pathways

News

Real-World Economic and Clinical Outcomes of Pegfilgrastim via Prefilled Syringe vs On-Body Injector

03/02/2022

Marta Rybczynski ;

Study findings report no clinically meaningful differences in febrile neutropenia incidence, HCRU, or costs between on-body injector and prefilled syringe methods of pegfilgrastim administration.

Study findings report no...

03/02/2022

Journal of Clinical Pathways

Conference Coverage

10/04/2021

Marta Rybczynski ;

According to a study presented at the 2021 ASCO Quality Care Symposium, cost-related prescription nonadherence is associated with higher health care cost responsibility in cancer survivors, especially for those living in rural compared to...

According to a study presented...

10/04/2021

Journal of Clinical Pathways

Conference Insider

Comparing Outcomes of Autologous Stem Cell Transplant vs Bortezomob-Melphalan-Prednisone for the Treatment of Multiple Myeloma

04/29/2022

Marta Rybczynski ;

Kathryn Maples, PharmD, BCOP, and Joseph Kalis, PharmD, BCOP, reflect on the utilization of an early or delayed ASCT for MM, as well as the role of the ASCT now that novel therapies such as daratumumab and carfilzomib are being introduced in...

Kathryn Maples, PharmD, BCOP,...

04/29/2022

Clinical Pathways